Access to Global Disease Innovation
Boston University School of Law
November 15, 2006
The pharmaceutical IP system works well in high-income countries able to afford government subsidies and social insurance. It does not work for the poor in low and middle-income countries. For global diseases (Types I and II), innovation is assured by high-income country markets alone, permitting an accommodation for the poor in low and medium-income countries such as a patent buyout or other access programs which support equitable access without damaging optimal innovation incentives.
Number of Pages in PDF File: 7
Keywords: intellectual property, IP, access, innovation, essential medicines, patent, pharmaceutical
Date posted: November 16, 2006
© 2016 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollobot1 in 0.156 seconds